NCT02397707View on ClinicalTrials.gov

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

March 24, 2015

Primary Completion Date

March 4, 2016

Study Completion Date

March 4, 2016

Conditions

HCV Infection

Interventions

DRUG

Voxilaprevir

100 mg tablet administered orally

Trial Locations (4)

1142

Auckland Clinical Studies, Auckland

32809

Orlando Clinical Research Center, Orlando

78215

Texas Liver Institute, San Antonio

81241

APEX GmbH, München

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY